60 μg of immune complexes (YIC)	placebo	HBeAg sero-conversion rate	1191	1309	HBeAg sero-conversion rate was 21.8%(17/78) and 9% (7/78) in the 60 μg YIC and placebo groups respectively (p = 0.03),
30 μg YIC, 60 μg of YIC	placebo	adverse events	22980	23190	The occurrence of serious adverse events calculated according to the intent-to-treat principle was 5.1% (4/79), 3.6% (3/83), and 5.0% (4/80) in the placebo, 30 μg YIC and 60 μg YIC groups respectively (p>0.05).
